UNAIDS Executive Director Winnie Byanyima speaks during the Launch of HIV Prevention Project in Johannesburg, South Africa, ...

Talking with the North Carolina Harm Reduction Coalition’s Loftin Wilson about the coalition’s work, how the opioid epidemic ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Celebrating the stories of PATF and Allies FEATURING: Kathi Boyle, Stuart Fisk, Tammy Frech, DJ Stemmler & Pam Vingle, Nachum Golan & Steve Hough, Alan Jones, ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...

Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...

A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.

Uganda has recorded major gains against HIV, with significant declines in prevalence, new infections, and AIDS-related deaths, but emerging concerns among young people and persistent mother-to-child ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...